Publication Name	World Journal of Clinical Urology
Manuscript ID	6693
Country	Italy

Received	2013-10-27 11:07
Peer-Review Started	2013-10-29 11:44
To Make the First Decision	2013-12-02 11:43
Return for Revision	2013-12-04 09:41
Revised	2013-12-07 23:56
Second Decision	2014-02-18 11:59
Accepted by Journal Editor-in-Chief
Accepted by Company Editor-in-Chief	2014-02-18 12:29
Articles in Press
Publication Fee Transferred
Edit the Manuscript by Language Editor
Typeset the Manuscript	2014-03-18 12:31
Publish the Manuscript Online	2014-03-25 11:20

ISSN	2219-2816 (online)
Open Access
Copyright
Article Reprints	For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
Permissions	For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
Publisher	Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
Website	http://www.wjgnet.com

Category	Oncology
Manuscript Type	Review
Article Title	“Targeting” renal cell carcinoma patients with “targeted” agents: Are we there yet?
Manuscript Source	Invited Manuscript
All Author List	Francesca Maines, Sara Pilotto, Michele Milella, Francesco Massari, Vanja Vaccaro, Alessandra Felici, Emilio Bria and Giampaolo Tortora
Funding Agency and Grant Number	Funding Agency Grant Number Italian Association for Cancer Research MFAG 14282 Italian Association for Cancer Research 11930 Italian Association for Cancer Research 5X1000 12182 Italian Association for Cancer Research 12214 Italian Ministry of Education, Universities and Research (MIUR) - Interest National Research Project 2009X23L78_005
Corresponding Author	Emilio Bria, MD, Medical Oncology, Azienda Ospedaliera Universitaria Integrata, University of Verona, P.zza L.A. Scuro 10, 37234 Verona, Italy. emiliobria@yahoo.it
Key Words	Biomarkers; Renal cell carcinoma; Prognostic biomarker; Predictive biomarker; Vascular endothelial growth factor tyrosine kinase inhibitors; Mammalian target of rapamycin inhibitors
Core Tip	To date, there are no fully validated biomarkers for daily clinical use in RCC treatment and the therapeutic decisions still depend exclusively on morphological and clinical criteria. Predictive markers of response are not yet available and consequently, all patients continue to be exposed to potentially toxic therapies without certainty of clinical benefit. The identification of reliable biomarkers could represent the turning point of the personalized treatment in RCC. Therefore, the design of clinical trials based on a biomarkers-approach is highly desirable in order to minimize costs and risks of treatments and to maximize the benefit to the patient.
Publish Date	2014-03-25 11:20
Citation	Maines F, Pilotto S, Milella M, Massari F, Vaccaro V, Felici A, Bria E, Tortora G. “Targeting” renal cell carcinoma patients with “targeted” agents: Are we there yet? World J Clin Urol 2014; 3(1): 9-19
URL	http://www.wjgnet.com/2219-2816/full/v3/i1/9.htm
DOI	http://dx.doi.org/10.5410/wjcu.v3.i1.9

Full Article (PDF)	wjcu-3-9.pdf
Full Article (Word)	wjcu-3-9.doc
Manuscript File	6693-Review.doc
Answering Reviewers	6693-Answering reviewers.pdf
Copyright License Agreement	6693-Copyright assignment.pdf
Peer-review Report	6693-Peer review(s).pdf
Scientific Editor Work List	6693-Scientific editor work list.doc